SAVINGS DEADLINE EXPIRES:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San DiegoMain Conference - Day 2 (May 9)keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference - Day 2 (May 9)
keyboard_arrow_leftSearch & Filter
search
Streams
Main Conference - Day 2 (May 9)
search
Streams
Main Conference - Day 2 (May 9) 7:30am - 7:45am15 mins
Registration
Breakfast Spotlight Presentations
Main Conference - Day 2 (May 9) 7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 1
Blockmer Technology: Solid-phase, Liquid-phase, and Flow Synthesis
- Masanori Kataoka, Ph.D. - CEO, NATiAS Inc.
Main Conference - Day 2 (May 9) 7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 2
Ajinomoto TBC
Main Conference - Day 2 (May 9) 7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 3
GenScript TBC
Concurrent Tracks
Main Conference - Day 2 (May 9) 8:25am - 8:30am5 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairman’s Remarks: Novel Oligonucleotide Discovery and Chemistry
- Troels Koch, PhD - Senior Vice President, Chemistry, MiNa Therapeutics
Main Conference - Day 2 (May 9) 8:25am - 8:30am5 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Chairman’s Remarks: Oligonucleotide Analytics
- Claus Rentel, PhD - Vice President, Analytical Development/QC, Ionis Pharmaceuticals, Inc.
Main Conference - Day 2 (May 9) 8:25am - 8:30am5 mins
Peptide Discovery to CMC
Chairman’s Remarks: Peptides for Cardio-Metabolic Disorders
- Florence Brunel, PhD - Senior Principal Scientist, Novo Nordisk
Main Conference - Day 2 (May 9) 8:25am - 8:30am5 mins
mRNA Technology and Applications
Chairman’s Remarks: mRNA Discovery to Manufacturing
Main Conference - Day 2 (May 9) 8:25am - 8:30am5 mins
Targeted Therapies and Delivery of Macromolecules
Chairwoman’s Remarks: Novel Delivery of Macromolecules
- Stephen Spagnol, PhD - Director, Enabling Technologies, Merck
Main Conference - Day 2 (May 9) 8:30am - 9:00am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Controlling siRNA Activity with Colored Lights
- Jean-Paul Desaulniers, PhD - Professor in Chemistry, Ontario Tech University
Main Conference - Day 2 (May 9) 8:30am - 9:00am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
The Relevance of Denatured- and Non-denatured LC Methods in Impurity Profiling of si-RNA Oligonucleotide Products
- Llias Jimidar, PhD - Associate Director Scientific Integration, Janssen R&D
Main Conference - Day 2 (May 9) 8:30am - 9:00am30 mins
Peptide Discovery to CMC
Engineering a Long-acting Relaxin ThP - AZD3427
- Monika Papworth, PhD - Principal Scientist, Biologics Engineering, AstraZeneca R&D
Main Conference - Day 2 (May 9) 8:30am - 9:00am30 mins
mRNA Technology and Applications
Liver-Tropic Helper Lipids (LTHL) for mRNA Therapeutics, Gene Therapy, and Gene Editing Platforms
- Ashish Sarode, PhD - Associate Director, Formulation and Delivery, Sanofi
Main Conference - Day 2 (May 9) 8:30am - 9:00am30 mins
Targeted Therapies and Delivery of Macromolecules
Targeted LNP-mRNA Platform for in vivo Cellular Reprogramming
- Hamideh Parhiz, PhD - Research Assistant Professor of Medicine, University of Pennsylvania
Main Conference - Day 2 (May 9) 9:00am - 9:30am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Impact of Phosphoryl Guanidine on Oligonucleotide Pharmacology in Preclinical and Clinical Studies
- Chandra Vargeese, PhD - Chief Technology Officer, WAVE Life Sciences
Main Conference - Day 2 (May 9) 9:00am - 9:30am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Analytical Development of Anti-Sense Oligonucleotides with 2’ NMA Chemistry
- Rasika Phansalkar, Ph.D. - Senior Scientist, Analytical Development, Biogen
Main Conference - Day 2 (May 9) 9:00am - 9:30am30 mins
Peptide Discovery to CMC
Identification of an Oral PCSK9-LDLR Disruptor
- Lauren Monovich - Head of Cardiovascular and Metabolism Chemistry, Novartis
Main Conference - Day 2 (May 9) 9:00am - 9:30am30 mins
mRNA Technology and Applications
Development of an mRNA-based Universal Influenza Vaccine
- Norbert Pardi, PhD - Research Assistant Professor of Medicine, University of Pennsylvania
Main Conference - Day 2 (May 9) 9:00am - 9:30am30 mins
Targeted Therapies and Delivery of Macromolecules
Delivery in a Nutshell(TM): Activity-informed Design of Cationic Peptoids with Enhanced Efficacy for the Uptake and Expression of mRNA Therapeutics
- Colin McKinlay, PhD - Senior Director, Chemistry and Delivery Technology, Nutcracker Therapeutics
Main Conference - Day 2 (May 9) 9:30am - 10:00am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Unlocking the Potential of Innovative Editing Oligonucleotides (EONs) to Address Liver Originated Disorders
- Gerard Platenburg, PhD - Chief Scientific Officer, ProQR Therapeutics
Main Conference - Day 2 (May 9) 9:30am - 10:00am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Sequencing and Characterization of Therapeutic RNAs
- Alexandre Goyon, PhD - Principal Scientist, Genentech
Main Conference - Day 2 (May 9) 9:30am - 10:00am30 mins
Peptide Discovery to CMC
Salient Features and Clinical Development of FGF21 Analog Efruxifermin in NASH
- Reshma Shringarpure, PhD - VP, Clinical Research and Medical Affairs, Akero Therapeutics
Main Conference - Day 2 (May 9) 9:30am - 10:00am30 mins
mRNA Technology and Applications
Nucleic Acid Delivery Systems for RNA Therapy and Genome Editing
- Daniel Anderson, Ph.D. - Professor, Chemical Engineering, Massachusetts Institute of Technology
Main Conference - Day 2 (May 9) 9:30am - 10:00am30 mins
Targeted Therapies and Delivery of Macromolecules
Selective Organ Targeting (SORT) LNP Platform and Applications in Therapeutic Programs
- Sakya Mohapatra - Director, Formulation Development, Recode Therapeutics
Main Conference - Day 2 (May 9) 10:00am - 10:45am45 mins
Networking Refreshment Break in Poster and Exhibit Hall
Main Conference - Day 2 (May 9) 10:45am - 11:15am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
A Novel Approach to Improved Distribution, Durability, and Potency of RNAi across the CNS
- Aimee Jackson, PhD - Chief Scientific Officer, Atalanta Therapeutics
Main Conference - Day 2 (May 9) 10:45am - 11:15am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
LC UV MS methods for Analysis of Therapeutic Oligonucleotides and mRNA
- Martin Gilar, PhD - Scientific Fellow, Waters Corporation
Main Conference - Day 2 (May 9) 10:45am - 11:15am30 mins
Peptide Discovery to CMC
Beyond GLP-1 Receptor Agonists: Examining Innovative Mechanisms of Action & Clinical Data for the Treatment of Obesity and NASH
- M.Scott Harris, MD - Chief Medical Officer, Altimmune
Main Conference - Day 2 (May 9) 10:45am - 11:15am30 mins
mRNA Technology and Applications
From Enzyme to mRNA: Improved RNA polymerases and in vitro Transcription Processes for Efficient Manufacturing of High-quality mRNA
- Helge Zieler, PhD - Founder & President, Primordial Genetics
Main Conference - Day 2 (May 9) 10:45am - 11:15am30 mins
Targeted Therapies and Delivery of Macromolecules
Beyond Delivery: Programming Information Molecules to Specific Cells and Tissues
- Guillaume Pfefer, PhD - CEO, Senda Biosciences
Main Conference - Day 2 (May 9) 11:15am - 11:45am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Late Breaking Presentation
Main Conference - Day 2 (May 9) 11:15am - 11:45am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Characterization of Synthetic Oligonucleotides Leveraging Multiple Modes and Dimensions of Liquid Chromatography and Mass Spectrometry
- Todd Maloney, PhD - Executive Director, Synthetic Molecule Design and Development, Eli Lilly & Co
Main Conference - Day 2 (May 9) 11:15am - 11:45am30 mins
Peptide Discovery to CMC
The Novel GIP, GLP-1, And Glucagon Triple Receptor Agonist LY3437943: From Discovery to Clinical Proof-of-Concept
- Hongchang Qu - Senior Director, Chemistry, Eli Lilly & Company
Main Conference - Day 2 (May 9) 11:15am - 11:45am30 mins
mRNA Technology and Applications
Late Breaking Presentation
Main Conference - Day 2 (May 9) 11:15am - 11:45am30 mins
Targeted Therapies and Delivery of Macromolecules
Lipid Nanoparticles for mRNA therapeutics, Cancer Immunotherapy and Cell Therapy
- Yizhou Dong, PhD - Professor, Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai
Main Conference - Day 2 (May 9) 11:45am - 12:15pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Late Breaking Presentation
Main Conference - Day 2 (May 9) 11:45am - 12:15pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Analytical Approaches for the Determination of Deaminated Degradation Species of Therapeutic Oligonucleotides
- Brandon Bock - Associate Director, Analytical Development/QC, Ionis Pharmacueitcals
Main Conference - Day 2 (May 9) 11:45am - 12:15pm30 mins
Peptide Discovery to CMC
Discovery and Development of Cagrilintide for the Treatment of Obesity
- Brian Finan, PhD - Vice President - Obesity Research, Novo Nordisk
Main Conference - Day 2 (May 9) 11:45am - 12:15pm30 mins
mRNA Technology and Applications
Late Breaking Presentation
Main Conference - Day 2 (May 9) 11:45am - 12:15pm30 mins
Targeted Therapies and Delivery of Macromolecules
Late Breaking Presentation
Main Conference - Day 2 (May 9) 12:15pm - 12:20pm5 mins
Oligonucleotide Discovery, Preclinical and Clinical
Transition to Spotlight Presentation Rooms
Main Conference - Day 2 (May 9) 12:15pm - 12:20pm5 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Transition to Spotlight Presentation Rooms
Main Conference - Day 2 (May 9) 12:15pm - 12:20pm5 mins
Peptide Discovery to CMC
Transition to Spotlight Presentation Rooms
Main Conference - Day 2 (May 9) 12:15pm - 12:20pm5 mins
mRNA Technology and Applications
Transition to Spotlight Presentation Rooms
Main Conference - Day 2 (May 9) 12:15pm - 12:20pm5 mins
Targeted Therapies and Delivery of Macromolecules
Transition to Spotlight Presentation Rooms
Spotlight Presentations
Main Conference - Day 2 (May 9) 12:20pm - 12:50pm30 mins
Spotlight Presentation 1
Going Green: Sustainability Solutions in Oligonucleotide Manufacturing
- Sven Warhaut - Project Lead GMP & Large Scale Production, BioSpring
Main Conference - Day 2 (May 9) 12:20pm - 12:50pm30 mins
Spotlight Presentation 2
A Challenge to Chemical Synthesis of High Quality RNAs up to 200mer
- Takashi Hara, PhD - Research Scientist R&D, Sumitomo Chemical Co., Ltd.
Main Conference - Day 2 (May 9) 12:20pm - 12:50pm30 mins
Spotlight Presentation 3
Strategies Towards Green & Cost-Efficient Peptide Manufacturing
- Eike-Fabian Sachs, PhD - Head of Development Frankfurt, CordenPharma International GmbH
Main Conference - Day 2 (May 9) 12:20pm - 12:25pm5 mins
Spotlight Presentation 4
Asahi Kasei TBC
Main Conference - Day 2 (May 9) 12:20pm - 12:50pm30 mins
Spotlight Presentation 5
Millipore TBC
Main Conference - Day 2 (May 9) 12:50pm - 1:55pm65 mins
Networking Luncheon in Poster and Exhibit Hall
Concurrent Tracks
Main Conference - Day 2 (May 9) 1:55pm - 2:00pm5 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairman’s Remarks
Main Conference - Day 2 (May 9) 1:55pm - 2:00pm5 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Chairperson's Remarks: Oligonucleotide Development and Manufacturing
- Doug Brooks, PhD - Principal Consultant, Matapalo LLC
Main Conference - Day 2 (May 9) 1:55pm - 2:00pm5 mins
Peptide Discovery to CMC
Chairman’s Remarks: Green Chemistry in Peptide Manufacturing
- Trishul Shah, M.S. - Director Business Development, PolyPeptide Laboratories Inc.
Main Conference - Day 2 (May 9) 1:55pm - 2:00pm5 mins
mRNA Technology and Applications
Chairman’s Remarks: Analytical Characterization of mRNA
- Andreas Kuhn, PhD - Vice President RNA Biochemistry & Manufacturing, BioNTech SE
Main Conference - Day 2 (May 9) 1:55pm - 2:00pm5 mins
Targeted Therapies and Delivery of Macromolecules
Chairman’s Remarks: Targeted Radiopharmaceuticals and Imaging
- Ved Srivastava, PhD - Vice President of Peptide Chemistry, Atkis Oncology
Main Conference - Day 2 (May 9) 2:00pm - 2:30pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
GalAhead: Novel GalNAc RNAi Platform and Programs
- Dmitry Samarsky, PhD - Chief Technology Officer, Sirnaomics
Main Conference - Day 2 (May 9) 2:00pm - 2:30pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Process Development of Therapeutic siRNA Conjugates Enabling Rapid Clinical Development
- Brendan Mowery, PhD - Senior Chemist III, Development Chemistry, Arrowhead Pharmaceuticals
Main Conference - Day 2 (May 9) 2:00pm - 2:30pm30 mins
Peptide Discovery to CMC
Entering the Era of SPPS Productions without DMF
- Martin Rosenberg, PhD - Development Scientist, CMC API Development, Novo Nordisk
Main Conference - Day 2 (May 9) 2:00pm - 2:30pm30 mins
mRNA Technology and Applications
Analytical Strategies Enabling Rapid and Nimble mRNA Product Development
- David Cirelli - Senior Director, Analytical Research & Development, Pfizer
Main Conference - Day 2 (May 9) 2:00pm - 2:30pm30 mins
Targeted Therapies and Delivery of Macromolecules
Advancing the Science of Radiopharmaceutical Therapy: A Renewed Hope for New Cancer Treatments
- Abhi Bhat, PhD - Senior VP Chemistry and Head of Discovery, Rayze Bio
Main Conference - Day 2 (May 9) 2:30pm - 3:00pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Therapeutic Targeting of a Pathological MicroRNA in Duchenne Muscular Dystrophy
- Anders Naar, Ph.D. - Founder, Elenae Therapeutics
Main Conference - Day 2 (May 9) 2:30pm - 3:00pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
USP Tools to Support the Quality Assessment of Oligonucleotide Starting Materials
- Kevin Carrick, Ph.D. - Director, Science and Standards, Biologics, United States Pharmacopeia
Main Conference - Day 2 (May 9) 2:30pm - 3:00pm30 mins
Peptide Discovery to CMC
Replacing DMF by Greener Solvents for Peptide Synthesis: Challenges and Opportunities
- Olivier Ludemann-Hombourger, PhD - Director, Global Innovation and Technology, PolyPeptide Group
Main Conference - Day 2 (May 9) 2:30pm - 3:00pm30 mins
mRNA Technology and Applications
Integrity Analysis of mRNA: Characterization of Break-off Transcripts and Degradation Products
- Simon Klenk, PhD - Director RNA Analytics, RNA Biochemistry, BioNTech SE
Main Conference - Day 2 (May 9) 2:30pm - 3:00pm30 mins
Targeted Therapies and Delivery of Macromolecules
Pb-212 Based Targeted Alpha-particle Radiopharmaceutical Therapeutics
- Michael Schultz, PhD - Chief Science Officer, Viewpoint Molecular Targeting
Main Conference - Day 2 (May 9) 3:00pm - 3:30pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Positive Results from a First-in-Human Study Support Continued Development of PGNEDO51 for the Treatment of Duchenne Muscular Dystrophy (DMD)
- James McArthur, Ph.D. - CEO and President, PepGen, Inc.
Main Conference - Day 2 (May 9) 3:00pm - 3:30pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Omission of Column Washing Operations in the Solid Phase Synthesis of Oligonucleotides
- Li Xiao, PhD - Senior Scientist, ASO Development and Manufacturing, Biogen
Main Conference - Day 2 (May 9) 3:00pm - 3:30pm30 mins
Peptide Discovery to CMC
Aqueous Templated Peptide Synthesis- the Green Revolution
- Sara Ten Have, PhD - CEO and Head Scientist, Origin Peptides
Main Conference - Day 2 (May 9) 3:00pm - 3:30pm30 mins
mRNA Technology and Applications
Advances in Capillary Electrophoresis (CE) Analytical Techniques are Enabling the RNA Vaccine Revolution
- Andrew Geall, PhD - Co-founder and Chief Development Officer, Replicate Bioscience
Main Conference - Day 2 (May 9) 3:00pm - 3:30pm30 mins
Targeted Therapies and Delivery of Macromolecules
Discovery and Development of Novel Peptide-Based Radiopharmaceuticals
- Benjamin Larimer - Assistant Professor, University of Alabama
Main Conference - Day 2 (May 9) 3:30pm - 4:15pm45 mins
Networking Refreshment Break in Poster and Exhibit Hall
Main Conference - Day 2 (May 9) 4:15pm - 4:45pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Antisense Oligonucleotide Therapy to Pre-kallikrein in the Treatment of Patients with Hereditary Angioedema (HAE)
- Kenneth Newman, M.D. - Vice President, Clinical Development, Ionis Pharmaceuticals
Main Conference - Day 2 (May 9) 4:15pm - 4:45pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Manufacturing and Scale-up at Light Speed - Producing and Scaling Up An Oligo to Save Lives Now!!
- Chris Oswald - Founder, Owner, and Principal Consultant, Coswald Consulting LLC
Main Conference - Day 2 (May 9) 4:15pm - 4:45pm30 mins
Peptide Discovery to CMC
Solvents, the Key Parameter for Greening Solid-Phase Peptide Synthesis
- Fernando Albericio, PhD - Research Professor, School of Chemistry, University of Kwazulu-Natal
Main Conference - Day 2 (May 9) 4:15pm - 4:45pm30 mins
mRNA Technology and Applications
Cell Based Potency Assay for mRNA-LNP Drug Product Analysis
- Vibha Yadav, PhD - Principal Scientist, Ultragenyx Pharmaceutical
Main Conference - Day 2 (May 9) 4:15pm - 4:45pm30 mins
Targeted Therapies and Delivery of Macromolecules
Molecular Imaging and Therapy for Patients with Breast Cancer
- Gary Ulaner, MD, PhD - James & Pamela Muzzy Endowed Chair in Molecular Imaging and Therapy, Hoag Family Cancer Institute
Main Conference - Day 2 (May 9) 4:45pm - 5:15pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Oligonucleotide Clinical Update
- Bob Brown, PhD - Chief Scientific Officer, EVP, R&D, Dicerna Pharmaceuticals
Main Conference - Day 2 (May 9) 4:45pm - 5:15pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Engineering Evolution for Manufacturing - Growing Capability and Capacity
- Mary Gibson - Associate Vice President Engineering and Facilities, Agilent Technologies
Main Conference - Day 2 (May 9) 4:45pm - 5:15pm30 mins
Peptide Discovery to CMC
Biocatalysis for Green Manufacturing of Amino Acids
- Christina Boville, PhD - Co-founder & CEO, Aralez Bio
Main Conference - Day 2 (May 9) 4:45pm - 5:15pm30 mins
mRNA Technology and Applications
Analytical Characterization Strategies for Circular RNA
- Benjamin Maynor, PhD - Senior Vice President, CMC, Orna Therapeutics
Main Conference - Day 2 (May 9) 4:45pm - 5:15pm30 mins
Targeted Therapies and Delivery of Macromolecules
Pretargeted PET Imaging of Antisense Oligonucleotides in the Brain
- Thomas Pickel, PhD - Scientist II, Technical Development, Biogen
Main Conference - Day 2 (May 9) 5:15pm - 5:45pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Late Breaking Presentation
Main Conference - Day 2 (May 9) 5:15pm - 5:45pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Intelligent Use of Facilities in Oligonucleotide Manufacturing
- Brendan Nichols - Process Engineer, CRB
Main Conference - Day 2 (May 9) 5:15pm - 5:45pm30 mins
Peptide Discovery to CMC
Numaswitch – A Future-proof Production Platform to Sustainably Access Peptides and Proteins
- Liv Kaser - Business Development Manager, Numaferm
Main Conference - Day 2 (May 9) 5:15pm - 5:45pm30 mins
mRNA Technology and Applications
mRNA Characterization in Analytical Development
- Glenn Milton, PhD - Analytical Development Scientist, Moderna
Main Conference - Day 2 (May 9) 5:15pm - 5:45pm30 mins
Targeted Therapies and Delivery of Macromolecules
Supply Chain Considerations for Radiopharmaceuticals
- Kevin Staton - Vice President, CDMO Project Management, Evergreen Theragnostics
Main Conference - Day 2 (May 9) 5:45pm - 6:45pm60 mins
Networking Reception in Poster and Exhibit Hall
Get the latest event updates
Sign up to get the latest event updates and information.
Filter
Streams
Choose Day
- Download Agenda
- Pre-Conference Workshops (May 7)Pre-Conference Workshops (May 7)
- Main Conference - Day 1 Keynote Sessions (May 8)Main Conference - Day 1 Keynote Sessions (May 8)
- Main Conference - Day 2 (May 9)Main Conference - Day 2 (May 9)
- Main Conference - Day 3 (May 10)Main Conference - Day 3 (May 10)